Clinical Trials Logo

Stroke clinical trials

View clinical trials related to Stroke.

Filter by:

NCT ID: NCT06243133 Not yet recruiting - Ischemic Stroke Clinical Trials

Pair Antiplatelet THerapy in Ischemic Stroke With Intracranial Artery Stenosis

PATH-ICAS
Start date: July 1, 2024
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to learn about efficacy and safety of dual antiplatelet therapy in ischemic stroke with intracranial artery stenosis. The main question it aims to answer are: whether aspirin combined with clopidogrel for 3 month is better than 1 months for patients with non-cardiogenic cerebral infarction with intracranial artery stenosis. Participants will get dual antiplatelet therapy (aspirin plus clopidogrel) for 1 month or 3 months within 7 days of the first stroke. Researchers will compare experimental group (3 months dual antiplatelet therapy) with comparison group (1 month dual antiplatelet therapy), to see if experimental group would reduce stroke recurrence or mortality, and increase bleeding and other adverse prognosis.

NCT ID: NCT06242366 Recruiting - Ischemic Stroke Clinical Trials

Transitional Care Program in Stroke Patients With Hemiplegia.

Start date: February 7, 2024
Phase: N/A
Study type: Interventional

This study examines the effects of a transitional care program in stroke patients on self-care behavior, quality of life, and hospital readmission. The research conceptual framework is based on the Transitional Care Model by Naylor. Sixty participants with stroke patients at Charoenkrung Pracharak Hospital will be recruited. These participants are stratified by block randomization using NIHSS score and divided into 2 groups; a control group (n=30) and an intervention group (n=30). The program consisted of 2 phases: 1) Phase I during hospital admission and 2) Phase II following hospital discharge

NCT ID: NCT06242145 Recruiting - Ischemic Stroke Clinical Trials

Clopidogrel Versus Cilostazol in Large-vessel Ischemic Stroke

Start date: February 1, 2024
Phase: Phase 3
Study type: Interventional

Along with the current clinical trial, the efficacy and safety of a 300 mg loading dose of ticagrelor administered within 24 hours of the first-ever large-vessel ischemic stroke compared to 200 mg cilostazol were assessed through NIHSS, mRS, and possible adverse effects.

NCT ID: NCT06242132 Recruiting - Ischemic Stroke Clinical Trials

Clopidogrel Versus Cilostazol in Ischemic Stroke

Start date: February 1, 2024
Phase: Phase 3
Study type: Interventional

Along with the current clinical trial, the efficacy and safety of a 300 mg loading dose of ticagrelor administered within 24 hours of the first-ever moderate to severe ischemic stroke compared to 200 mg cilostazol were assessed through NIHSS, mRS, and possible adverse effects.

NCT ID: NCT06241677 Not yet recruiting - Clinical trials for CVA (Cerebrovascular Accident)

Intravenous Thrombolytic Therapy in Acute Ischemic Stroke Patients on DOAC

DOAC-IVT
Start date: March 5, 2024
Phase: N/A
Study type: Interventional

Direct oral anticoagulants (DOAC) have emerged as safe and efficacious ischemic stroke prophylaxis for non-valvular atrial fibrillation (NVAF). All four DOACs - apixaban, dabigatran, edoxaban, rivaroxaban - were associated with lower risks of major bleeding compared to warfarin. Listed as core essential medicines by the World Health Organization, DOAC prescriptions have been surging worldwide. In Hong Kong, approximately 80,000 patients received DOACs from January 2009 through December 2022 according to the Hospital Authority registry. The widespread DOAC usage had created DOAC-specific clinical dilemmas that lack evidence-based treatment despite twenty years of prescribing experience. Ischemic stroke despite DOAC (IS-DOAC), in particular, may occur in up to 6% of DOAC users annually. Due to the in vivo anticoagulation effect, there had been concerns of intracerebral bleeding (ICH) with intravenous thrombolytic therapy (IVT) for acute IS-DOAC. Under the current guideline recommendations, most acute IS-DOAC are contraindicated to IVT (see Intravenous thrombolytic therapy), which resulted in only a small proportion of acute ISDOAC patients being able to receive IVT even if presented early. Nonetheless, our group found that majority of patients had a DOAC level of <50ng/mL only 24 hours after DOAC cessation (see work done by us), a level deemed clinically negligible and safe for thrombolytic therapy. Together with evolving clinical evidence discussed below, IS-DOAC patients maybe unnecessarily barred from IVT, thus compromised functional recovery. With robust pharmacokinetic and retrospective clinical evidence to support, it is hypothesized that IVT are safe in IS-DOAC patient. The investigators hereby propose a prospective multicenter study to determine the efficacy and safety of IVT in acute IS-DOAC.

NCT ID: NCT06241508 Not yet recruiting - Stroke Clinical Trials

The Modulatory Effect of Low-intensity Priming Intermittent Theta Burst Stimulation on Motor Cortex Poststroke: a Concurrent TMS-EEG Study

Start date: February 15, 2024
Phase: N/A
Study type: Interventional

Background: The optimization of the intensity of priming theta burst stimulation increases the probability of success in a randomized controlled trial. We hypothesize that priming intermittent theta burst stimulation (iTBS) with a low-intensity continuous theta burst stimulation (cTBS) will yield superior effects than our original priming protocol in healthy adults and patients after stroke. Methods: 15 healthy adults and 15 stroke patients will undergo three separate experimental conditions: a low-intensity priming stimulation (55% resting motor threshold [RMT] cTBS+70% RMT iTBS), a conventional-intensity priming stimulation (70% RMT cTBS+70% RMT iTBS), and a nonpriming control. The alterations in cortical excitation/inhibition and its impacts on motor behaviors will be evaluated following stimulation. Significance: The findings will inform future clinical trials investigating the optimized priming iTBS in promoting poststroke recovery.

NCT ID: NCT06241339 Available - Stroke Clinical Trials

Chronic Effect of Mat Pilates on Neuromotor, Cardiovascular Functions and Inflammatory Markers in Individuals Post-Stroke Stroke and High Blood Pressure

Start date: n/a
Phase:
Study type: Expanded Access

The Pilates method aims to develop conscious control of body movements. In the literature there are studies that relate the method to postural stabilization, joint rehabilitation, treatment of low back pain, cancer and chronic obstructive pulmonary disease. However, studies on the modality&#39;s potential for improving isokinetic and antihypertensive strength are scarce, particularly in post-stroke hemiparetic individuals with high blood pressure (BP). The objective of the study is to investigate changes in isokinetic strength and BP, in addition to functional capacity, balance, autonomic modulation, blood biomarkers and endothelial function in hemiparetic individuals due to stroke sequelae and/or with high BP (prehypertensive and hypertensive), after 12 weeks of training with Mat Pilates. Eligible volunteers will be randomly divided into a Mat Pilates group with stroke (GP-AVE), Mat Pilates group with high blood pressure (HA) (GP-HA), control group with stroke (GC-AVE) and control group with HA (GC-HA ). On the first and second visit, measurements of isokinetic strength, functional capacity, static and dynamic balance, heart rate variability, cardiac output, stroke volume, endothelial function, total peripheral vascular resistance and blood biomarkers will be carried out. In addition, 24-hour BP will be measured by ambulatory monitoring (ABPM). GP-AVE and GP-HA will participate in a 12-week Mat Pilates program, totaling 36 training sessions lasting approximately 60 minutes, with an increasing degree of difficulty and complexity throughout the training period. GC-AVE and GC-HA will be instructed to maintain their daily activities during the intervention period, then they will be invited to participate in the Mat Pilates program. The initial measurements will be repeated at the end of the intervention in the Mat Pilates and control groups. Intra and intergroup comparisons will be carried out for all outcomes, for a significance level set at p ≤ 0.05.

NCT ID: NCT06240468 Recruiting - Clinical trials for Acute Ischemic Stroke

Dynamic Changes in Human Microbiome Predict the Risk of Adverse Outcomes in Patients With Acute Ischemic Stroke: a Multicenter Prospective Cohort Study

Start date: February 10, 2022
Phase:
Study type: Observational

(1) The main purpose To explore the predictive value of human microbiome and its metabolome for adverse prognosis in patients with acute ischemic stroke (AIS). (2) Secondary purposes 1. To explore the characteristics of cross-regional disturbance of human microbiome in stroke patients; 2. To investigate the characteristics and rules of bacterial flora changes before and after recurrent apoplexy; 3. Markers closely related to AIS prognosis and cognitive emotional complications were excavated by metagenomic, metabolic, peptide and imaging groups. 4. To explore the relationship between serum markers of ultra early stage and prognosis.

NCT ID: NCT06239948 Completed - Stroke Clinical Trials

The Brain Symphony For Post-Stroke Rehabilitation

Start date: January 1, 2018
Phase: N/A
Study type: Interventional

Music listening intervention has made great strides in improving the condition of stroke survivors. Thus, this research explores the effects of music listening intervention on post-stroke survivors during rehabilitation by using P. Ramlee songs.

NCT ID: NCT06238206 Completed - Stroke Clinical Trials

What User-requirements Need to be Considered When Developing a Lower-limb Exoskeleton? A Qualitative Study.

Start date: January 17, 2024
Phase: N/A
Study type: Interventional

The goal of this study is to identify the needs and requirements of end-users regarding the implementation of a lower-limb exoskeleton in a remote home setting. The end-users include older adults with sarcopenia, post-stroke individuals and physiotherapists. The main question it aims to answer is: • What are the needs and requirements of the end-user population when developing a lower-limb exoskeleton that can be implemented in a remote home setting? Participants will engage in three separate focus group sessions, in which they will discuss the predetermined topics. Interactions between the participants will be guided by open questions.